Cas:13604-68-7 methyl 3-(butylamino)-2-methylpropanoate manufacturer & supplier

We serve Chemical Name:methyl 3-(butylamino)-2-methylpropanoate CAS:13604-68-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

methyl 3-(butylamino)-2-methylpropanoate

Chemical Name:methyl 3-(butylamino)-2-methylpropanoate
CAS.NO:13604-68-7
Synonyms:2-methyl-3-butylaminopropionic acid methyl ester
Molecular Formula:C9H19NO2
Molecular Weight:173.25300
HS Code:2922499990

Physical and Chemical Properties:
Melting point:N/A
Boiling point:229.9ºC at 760mmHg
Density:0.912g/cm3
Index of Refraction:1.43
PSA:38.33000
Exact Mass:173.14200
LogP:1.57610

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-methyl-3-butylaminopropionic acid methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-methyl-3-butylaminopropionic acid methyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-methyl-3-butylaminopropionic acid methyl ester Use and application,2-methyl-3-butylaminopropionic acid methyl ester technical grade,usp/ep/jp grade.


Related News: The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. 1-(3′-Trifluoromethanesulphonamido-4′,6′-dimethyl-phenyl)-pyrrolidin-2-one manufacturers SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 5-(2,6-Dichloro-phenoxy)-2-nitro-benzenesulfonamide suppliers Its approval has since been called into question, however, and the head of the FDA is now calling for a federal investigation looking into interactions between agency staff and the biotech company. 2-Bromo-isoindole-1,3-diylidenediamine vendor & factory.